1. Home
  2. GEN vs VTRS Comparison

GEN vs VTRS Comparison

Compare GEN & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gen Digital Inc.

GEN

Gen Digital Inc.

SELL

Current Price

$24.22

Market Cap

18.6B

Sector

Technology

ML Signal

SELL

Logo Viatris Inc.

VTRS

Viatris Inc.

SELL

Current Price

$18.43

Market Cap

18.7B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
GEN
VTRS
Founded
1982
1961
Country
United States
United States
Employees
N/A
30000
Industry
Computer Software: Prepackaged Software
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.6B
18.7B
IPO Year
1995
2019

Fundamental Metrics

Financial Performance
Metric
GEN
VTRS
Price
$24.22
$18.43
Analyst Decision
Buy
Buy
Analyst Count
10
12
Target Price
★ $32.33
$19.70
AVG Volume (30 Days)
★ 11.7M
8.1M
Earning Date
10-28-2026
11-05-2026
Dividend Yield
2.02%
★ 2.63%
EPS Growth
★ 52.43
N/A
EPS
★ 0.36
0.05
Revenue
$6,676,000,000.00
★ $14,299,900,000.00
Revenue This Year
$8.99
$3.44
Revenue Next Year
$6.24
$1.68
P/E Ratio
★ $68.88
$364.00
Revenue Growth
N/A
★ N/A
52 Week Low
$17.78
$9.92
52 Week High
$31.65
$18.43

Technical Indicators

Market Signals
Indicator
GEN
VTRS
Relative Strength Index (RSI) 46.25 67.02
Support Level $21.98 $15.94
Resistance Level $25.28 N/A
Average True Range (ATR) 0.80 0.47
MACD 0.40 0.04
Stochastic Oscillator 78.99 94.82

Price Performance

Historical Comparison
GEN
VTRS

About GEN Gen Digital Inc.

Gen is a cybersecurity pure-play that offers security, identity protection, and privacy solutions to individual consumers. The firm's cyber safety offerings, via brands such as Norton, Avast, and LifeLock, have long maintained their positions as some of the most recognizable consumer-focused security and identity-protection products.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: